Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • JnJ, Oklahoma to wrap...

    JnJ, Oklahoma to wrap up first trial over opioid crisis

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-21T09:00:04+05:30  |  Updated On 21 July 2019 9:00 AM IST
    JnJ, Oklahoma to wrap up first trial over opioid crisis

    Lawyers for Attorney General Mike Hunter and JnJ are set to deliver closing arguments in state court in Norman, Oklahoma following six weeks of testimony from current and former JnJ executives and victims of the epidemic.


    U.S: Oklahoma's attorney general is expected on Monday to urge a judge to find Johnson & Johnson (JnJ) responsible for flooding the market with painkillers and fueling the U.S. opioid epidemic, as the first trial in nationwide litigation over the drug crisis comes to an end.


    Lawyers for Attorney General Mike Hunter and J&J are set to deliver closing arguments in state court in Norman, Oklahoma following six weeks of testimony from current and former JnJ executives and victims of the epidemic.


    The case is one of more than 2,000 actions by state and local governments accusing drug manufacturers of contributing to an epidemic linked to a record 47,600 opioid overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.


    Read Also: Oklahoma judge denies motion to end case against drugmaker JnJ


    The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits, particularly in 1,900 cases pending in Ohio brought largely by cities and counties against JnJ and other companies.


    The federal judge overseeing that litigation has been pushing for a settlement ahead of an October trial.


    Oklahoma says that starting in the 1990s, New Jersey-based J&J used misleading marketing to push doctors to prescribe more opioids.


    The state claims that JnJ, which sold the painkillers Duragesic and Nucynta, marketed the opioids as "safe and effective for everyday pain" and downplayed their addictive qualities.


    The state has accused J&J of acting as the "kingpin" behind the epidemic and says it was motivated to boost prescriptions not only because it sold painkillers but because it also grew and imported raw materials opioid manufacturers like OxyContin maker Purdue Pharma LP used.


    J&J denies the allegations. Its lawyers have argued that its products made up a small share of opioids prescribed in Oklahoma and carried U.S. Food and Drug Administration-approved labels that warned of the addictive risks.


    Read Also: US government seeks part of Oklahoma $270 million opioid settlement


    The company says the state lacks evidence linking JnJ's marketing to doctors writing unwarranted opioid prescriptions or that it caused the epidemic.


    The company also has said that the state is seeking to stretch the bounds of a public nuisance statute in order to force J&J to pay up to $17.5 billion to remedy the crisis.


    Cleveland County District Judge Thad Balkman, who will hear the arguments, will rule at a later date.


    Purdue and Teva Pharmaceutical Industries Ltd were originally also defendants in the case. Purdue reached a $270 million settlement with the state in March and Teva settled for $85 million in June. Both deny wrongdoing. (Reporting by Nate Raymond in Boston; editing by Noeleen Walder and Steve Orlofsky)

    ClevelandDisease Control and PreventionDuragesicJ&JJnJJohnson and JohnsonkingpinMike HunterNormanNucyntaohioOklahomaopioidopioid crisisOxyContinpharmapharma companypharma newsPurduestate courtstate court in NormanTeva PharmaTeva Pharmaceutical Industries LtdThad BalkmanU S Centers for Disease Control and PreventionUS Centers
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok